GLP-1 "Arms Race" Broadens to Include Dozens of Companies — Neutral

LEXX   Accesswire — August 06, 2025

Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update. The market for obesity and diabetes control drugs such as GLP-1 is growing at faster rates than nearly anyone originally anticipated, with revenues now expected to exceed $150 billion by 2030.

image for news GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Cosmos Health secures financing of up to $300 million to develop an ETH-backed treasury, with remaining proceeds for growth and general working capital

image for news Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

MINNEAPOLIS--(BUSINESS WIRE)--Deluxe (NYSE: DLX), a trusted Payments and Data company, today announced it has completed the acquisition of CheckMatch from Kinexys by J.P. Morgan, the firm's industry-leading blockchain business unit. Consistent with the company's strategy, this acquisition will expand the Deluxe Payment Network (DPN) solution. CheckMatch is a service that digitizes the delivery of paper checks, enabling faster electronic conveyance, which was developed by Kinexys by J.P. Morgan.

image for news Deluxe Acquires CheckMatch from Kinexys by J.P. Morgan to Extend Digital Lockbox Payments Capability

Stacy Rasgon, Bernstein senior U.S. semiconductor analyst, joins 'Squawk Box' to discuss looming tariffs on semiconductors, impact on the chips sector, AMD's quarterly earnings results, and more.

image for news Bernstein's Stacy Rasgon on semiconductor tariffs, impact on sector and AMD Q2 results

Sail from Sydney to London on an Unforgettable Adventure Calling on 80 Ports in 34 Countries MIAMI , Aug. 6, 2025 /PRNewswire/ -- Oceania Cruises ® , the world's leading culinary- and destination-focused luxury cruise line, is redefining luxury global exploration with its new Kangaroo Route sailing, an extraordinary 129-day Around the World voyage visiting more than 80 ports across 34 countries and four continents, aboard the critically acclaimed Oceania Vista. Featuring overnight stays in Cairns, Shanghai, Tokyo, Singapore, Mumbai, Luxor and Bordeaux, bookings for this epic journey – a new segment of the 2027 Around the World cruise – …

image for news Oceania Cruises® Unveils a Global Journey of Discovery: The Kangaroo Route, aboard Oceania Vista®

CFC To Host Conference Call on Fiscal Year 2025 Financial Results — Neutral

NRUC   GlobeNewsWire — August 06, 2025

DULLES, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- The National Rural Utilities Cooperative Finance Corporation (CFC) will hold an investor conference call and webcast on Friday, August 8, at 10 a.m. Eastern Time. CFC CEO Andrew Don will provide a business update and CFC Senior Vice President and CFO Ling Wang will review CFC's fiscal year 2025 financial results.

image for news CFC To Host Conference Call on Fiscal Year 2025 Financial Results

Snap shares tumbled in premarket trading on Wednesday after Citizens downgraded the social media company following a second-quarter revenue miss. Analyst Andrew Boone cut his rating on the stock to market perform from market outperform and removed his previous $12 per share price target.

image for news Snap shares plunge 18% in premarket open after Citizens downgrade over Q2 miss

Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy — Negative

NVO   Investors Business Daily — August 06, 2025

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, Wegovy.

image for news Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy

Globalstar to Participate in Upcoming Investor Conferences — Neutral

GSAT   Business Wire — August 06, 2025

COVINGTON, La.--(BUSINESS WIRE)--Globalstar, Inc. (Nasdaq: GSAT) (“Globalstar” or the “Company”), a next-generation telecommunications infrastructure and technology provider, today announced that members of the Company will be participating at the following upcoming investor conferences: Morgan Stanley Media & Communications Corporate Access Day Date: Tuesday, August 12, 2025 Location: New York, NY Format: One-on-one or Group Meetings TD Securities Technology Growth Capital Summit Date: Thu.

image for news Globalstar to Participate in Upcoming Investor Conferences

Bentley Systems, Incorporated (BSY) Beats Q2 Earnings and Revenue Estimates — Positive

BSY   Zacks Investment Research — August 06, 2025

Bentley Systems, Incorporated (BSY) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.31 per share a year ago.

image for news Bentley Systems, Incorporated (BSY) Beats Q2 Earnings and Revenue Estimates

Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates — Positive

CRL   Zacks Investment Research — August 06, 2025

Charles River Laboratories (CRL) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.5 per share. This compares to earnings of $2.8 per share a year ago.

image for news Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates — Negative

ARVN   Zacks Investment Research — August 06, 2025

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.

image for news Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

Diebold Nixdorf, Incorporated (DBD) Misses Q2 Earnings Estimates — Negative

DBD   Zacks Investment Research — August 06, 2025

Diebold Nixdorf, Incorporated (DBD) came out with quarterly earnings of $0.6 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $1.16 per share a year ago.

image for news Diebold Nixdorf, Incorporated (DBD) Misses Q2 Earnings Estimates

Extreme Networks (EXTR) Q4 Earnings and Revenues Beat Estimates — Positive

EXTR   Zacks Investment Research — August 06, 2025

Extreme Networks (EXTR) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to a loss of $0.08 per share a year ago.

image for news Extreme Networks (EXTR) Q4 Earnings and Revenues Beat Estimates

Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates — Negative

GERN   Zacks Investment Research — August 06, 2025

Geron (GERN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.

image for news Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates

Rivian Is Doomed — Negative

RIVN   24/7 Wall Street — August 06, 2025

Small electric vehicle (EV) companies aren't going to make it, especially as demand for EVs in the U.S.

image for news Rivian Is Doomed

Ceragon Networks (CRNT) Q2 Earnings Match Estimates — Positive

CRNT   Zacks Investment Research — August 06, 2025

Ceragon Networks (CRNT) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.11 per share a year ago.

image for news Ceragon Networks (CRNT) Q2 Earnings Match Estimates

Valvoline (VVV) Surpasses Q3 Earnings and Revenue Estimates — Positive

VVV   Zacks Investment Research — August 06, 2025

Valvoline (VVV) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.45 per share a year ago.

image for news Valvoline (VVV) Surpasses Q3 Earnings and Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates — Negative

TRDA   Zacks Investment Research — August 06, 2025

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $1.55 per share a year ago.

image for news Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

Lucid Is Doomed — Negative

LCID   24/7 Wall Street — August 06, 2025

Lucid Group Inc. (NASDAQ: LCID) stock collapsed 7% after hours when it announced terrible earnings.

image for news Lucid Is Doomed